NEW ZEALAND GAZETTE, No. 65 — 22 JUNE 2017

Professor Alan Thurston, of Wellington
to be a member of the board of the New Zealand Artificial Limb Service for a term of three years commencing on 1 July 2017 and expiring on 30 June 2020.

Dated at Wellington this 8th day of June 2017.

HON ANNE TOLLEY, Minister for Social Development.

2017-go3125

Classification of Medicines

Pursuant to section 106(1) of the Medicines Act 1981, I, Chris James, Group Manager, Medsafe, Ministry of Health, acting under delegated authority, hereby declare the following:

1. The medicines listed in Schedule 1 to this notice are classified as prescription medicines.
2. The medicines listed in Schedule 2 to this notice are classified as restricted medicines.

Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological or mineral sources.

Unless specific reference is made otherwise, every reference applies also to medicines that are:

a. preparations and admixtures containing any proportion of any substance listed in the notice.

b. salts and esters of any substance listed in the notice.

c. preparations or extracts of biological materials listed in the notice.

d. salts or oxides of elements listed in the notice.

Unless specific reference is made otherwise, every reference to a medicine applies:

i. if the medicine is in an injection or eye preparation, to any concentration of that medicine; and

ii. if the medicine is not in an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.

Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise.

Schedule 1

Prescription Medicines

Desogestrel; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister of Health or Director-General to their distribution as medicines, containing not more than six months’ supply, by a registered pharmacist who has successfully completed the approved training programme

Ethinyloestradiol; except when supplied at a strength of 35 micrograms or less in combination with either levonorgestrel or norethisterone for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister of Health or Director-General to their distribution as medicines, containing not more than six months’ supply, by a registered pharmacist who has successfully completed the approved training programme

Levonorgestrel; except when specified elsewhere in this notice; except in medicines for use as emergency post-coital contraception when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand approved training programme on oral contraception, when sold in the manufacturer’s original pack that has received the consent of the Minister of Health or Director-General to their distribution as medicines, containing not more than six months’ supply, by a registered pharmacist who has successfully completed the approved training programme

Lisdexamfetamine

Norethisterone; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand approved training programme